NJ State Employees Deferred Compensation Plan’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,000	Closed	-$499K	–	494
2023 Q2	$499K	Hold	13,000	–	–	0.07%	275
2023 Q1	$301K	Buy	+13,000	New	+$310K	0.05%	374
2017 Q1	–	Sell	-10,660	Closed	-$608K	–	390
2016 Q4	$608K	Hold	10,660	–	–	0.12%	254
2016 Q3	$663K	Hold	10,660	–	–	0.14%	235
2016 Q2	$603K	Hold	10,660	–	–	0.13%	241
2016 Q1	$786K	Hold	10,660	–	–	0.17%	205
2015 Q4	$1.5M	Hold	10,660	–	–	0.31%	102
2015 Q3	$1.03M	Buy	+10,660	New	+$1.27M	0.22%	151

NJ State Employees Deferred Compensation Plan's KDNY Position: Q3 2023 in Review

NJ State Employees Deferred Compensation Plan sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 13,000 shares — an estimated $499K sold.

NJ State Employees Deferred Compensation Plan first reported a position in KDNY in Q3 2015 and held it in 8 quarters. The position peaked at $1.5M in Q4 2015. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

NJ State Employees Deferred Compensation Plan reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 13,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $499K.
NJ State Employees Deferred Compensation Plan first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2015 and held it in 8 quarters.
NJ State Employees Deferred Compensation Plan's Chinook Therapeutics, Inc. Common Stock position peaked at $1.5M in Q4 2015.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2023, filed 8 Nov 2023.